CAMP4 – Talk Bio

Actionable Insights Powered by AI

Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

6 months ago talkbio0Tagged allergic diseases, Biotechnology, CAMP4, Inflammatory disorder, IPO, Nasdaq, Upstream Bio

Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases

BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases

7 months ago talkbio0Tagged Antisense, ASOs, BioMarin, CAMP4, genetic conditions, Hereditary Diseases, Oligonucleotides, regulatory RNA, RNA-targeting, Technology Platform

BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions